Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Boshuizen, Julia, Koopman, Louise A, Krijgsman, Oscar, Shahrabi, Aida, van den Heuvel, Elke Gresnigt–, Ligtenberg, Maarten A, Vredevoogd, David W, Kemper, Kristel +12 more·2018·Nature Medicine
DOI 10.1038/nm.4472

Cited by (230)

Items 101–200 of 230

  1. AXL – a new player in resistance to HER2 blockade
    Anna Adam‐Artigues, Enrique Javier Arenas, Joaquı́n Arribas, Aleix Prat, Juan Miguel Cejalvo · 2023 · Cancer Treatment Reviews
  2. Statistical analysis of longitudinal data on tumour growth in mice experiments
    Ioannis Zavrakidis, Katarzyna Jóźwiak, Michael Hauptmann · 2020 · Scientific Reports
  3. Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)
    Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center · 2022 · Cancer Innovation
  4. Hybrid Extracellular Vesicles‐Liposomes Camouflaged Magnetic Vesicles Cooperating with Bioorthogonal Click Chemistry for High‐Efficient Melanoma Circulating Tumor Cells Enrichment
    Ke Kang, Yujia Zhang, Xiaoxi Zhou, Yue Yu, Nanhang Zhu, Jia Cheng, Qiangying Yi, Yao Wu · 2023 · Advanced Healthcare Materials
  5. In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development
    Han Yin, Yue Hua, Songwei Feng, Yi Xu, Yue Ding, Sicong Liu, Dongsheng Chen, Furong Du, Gaolin Liang, Wenjun Zhan et al. · 2024 · Advanced Materials
  6. Targeting AXL in NSCLC
    Aubhishek Zaman, Trever Grant Bivona · 2021 · Lung Cancer Targets and Therapy
  7. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies
    Özgecan Dülgar, Tuğçe Kütük, Zeynep Eroglu · 2020 · American Journal of Clinical Dermatology
  8. Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells
    Ines Kozar, Demetra Philippidou, Christiane Margue, Lauren A. Gay, Rolf Renne, Stephanie Kreis · 2021 · Cancers
  9. The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma
    Barbara Montico, Giorgio Giurato, Giovanni Pecoraro, Annamaria Salvati, Alessia Covre, Francesca Colizzi, Agostino Steffan, Alessandro Weisz, Michele Maio, Luca Sigalotti et al. · 2021 · Molecular Oncology
  10. Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency
    Yanting Duan, Jiangqing Chen, Xianhui Meng, Longwei Liu, Kai Shang, Xiaoyan Wu, Yajie Wang, Zihan Huang, Houyu Liu, Yanjie Huang et al. · 2022 · Molecular Therapy
  11. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji, Yamada, Tadaaki, Hirai, Soichi, Katayama, Yuki, Fukui, Sarina, Sawada, Ryo, Tachibana, Yusuke, Matsui, Yohei, Nakamura, Ryota, Ishida, Masaki et al. · 2024 · Cancer Letters
  12. Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
    Aarti Tiwari, Saloni Rahi, Sidharth Mehan · 2020 · Current Drug Targets
  13. Antibody-drug conjugates: beyond current approvals and potential future strategies
    Siddharth Menon, Sagun Parakh, Andrew Mark Scott, Hui Kong Gan · 2022 · Exploration of Targeted Anti-tumor Therapy
  14. The role of yes activated protein (YAP) in melanoma metastasis
    Andrew Leask, John Nguyen, Angha Naik, Pratyusha Chitturi, Bruce L. Riser · 2024 · iScience
  15. Advanced Melanoma
    Alexandra M. Haugh, April K.S. Salama, Douglas Buckner Johnson · 2020 · Hematology/Oncology Clinics of North America
  16. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma
    Britt Van Renterghem, Agnieszka Woźniak, Patricia Garrido Castro, Patrick Franken, Nora Pencheva, Raf Sciot, Patrick Schöffski · 2022 · International Journal of Molecular Sciences
  17. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
    Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu et al. · 2020 · Cancer Medicine
  18. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
    Joshua E. Reuss, Laura Gosa, Stephen V. Liu · 2021 · Clinical Lung Cancer
  19. Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
    Chaitali Passey, Jenna L. Voellinger, Leonid V. Gibiansky, Rudy Gunawan, Leonardo Nicacio, Ibrahima Soumaoro, William D. Hanley, Helen R. Winter, Manish Gupta · 2023 · CPT Pharmacometrics & Systems Pharmacology
  20. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
    Jing Shi, Tao Jiao, Qian Guo, Weining Weng, Linjie Ma, Qing Zhang, Lijun Wang, Jianjian Zhang, Caiwei Chen, Yaling Huang et al. · 2023 · Cancer Research
  21. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects
    Winston Hibler, Glenn T Merlino, Yanlin Yu · 2023 · Cells
  22. The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts
    Benjamin Neuditschko, Lukas Janker, Laura Niederstaetter, Julia Brunmair, Katharina Krivanek, Sivan Izraely, Orit Sagi‐Assif, Tsipi Meshel, Bernhard K. Keppler, Giorgia Del Favero et al. · 2019 · Molecular & Cellular Proteomics
  23. Deciphering Melanoma Cell States and Plasticity with Zebrafish Models
    Jana Trávníčková, E. Elizabeth Patton · 2020 · Journal of Investigative Dermatology
  24. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
    Shiori Umemura, Yoshihiro Sowa, Yosuke Iizumi, Jo Kitawaki, Toshiyuki Sakai · 2020 · Cancer Science
  25. Novel AXL‑targeted agents overcome FLT3 inhibitor resistance in FLT3‑ITD+ acute myeloid leukemia cells
    Yi Liu, Jing Wei, Jiaxin Liu, Weina Ma, Yanting Duan, Dai‐Hong Liu · 2021 · Oncology Letters
  26. A Generic Antibody-Blocking Protein That Enables pH-Switchable Activation of Antibody Activity
    Lieuwe Biewenga, Robin T. Vermathen, Bas J. H. M. Rosier, Maarten Merkx · 2023 · ACS Chemical Biology
  27. Development of Personalized Strategies for Precisely Battling Malignant Melanoma
    Armond J. Isaak, GeGe R. Clements, Rand Gabriel M. Buenaventura, Glenn T Merlino, Yanlin Yu · 2024 · International Journal of Molecular Sciences
  28. Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer
    Dongguo Lin, Yanzhang Luo, Jueming Chen, Ziqing Ma, Hui Kang, X. Wang, Lihui Wang, Dayu Liu · 2025 · Microsystems & Nanoengineering
  29. Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies
    Yixin Zou, Tomonori Yaguchi · 2023 · Experimental Dermatology
  30. Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis
    Olga S. Cherepakhin, Zsolt B. Argényi, Ata S. Moshiri · 2021 · Cancers
  31. The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma
    Zaria Malindi, Stefan Barth, Heidi Abrahamse · 2022 · Biomedicines
  32. Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
    Sandra Goetze, Audrey van Drogen, Jonas B. Albinus, Kyle L. Fort, Tejas Gandhi, Damiano Robbiani, Véronique Laforte, Lukas Reiter, Mitchell Paul Levesque, Yue Xuan et al. · 2024 · Clinical Proteomics
  33. The epigenome and the many facets of cancer drug tolerance
    Paul C. Moore, Kurt W. Henderson, Marie Classon · 2023 · Advances in cancer research
  34. ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review
    Saurav Verma, Daniel Adam Breadner, Jacques Raphael · 2023 · Current Oncology
  35. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
    Bernhard Biersack, Lubna Hamid Tahtamouni, Michael Höpfner · 2024 · Receptors
  36. Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL
    Yingshi Chen, Yiwen Zhang, Siqi Chen, Weiwei Liu, Yingtong Lin, Hui Zhang, Fei Yu · 2021 · Pigment Cell & Melanoma Research
  37. Cell state plasticity in neuroblastoma
    Adam David Durbin, Rogier Versteeg · 2024 · EJC Paediatric Oncology
  38. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
    Anum Jalil, Melissa Donate, Jane Mattei · 2024 · Cancer Drug Resistance
  39. Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value
    Ahmad Najem, Jasper Wouters, Mohammad Krayem, Florian Rambow, Malak Sabbah, François Salès, Ahmad Hussein Awada, Stein Aerts, Fabrice Journé, Jean‐Christophe Marine et al. · 2021 · Frontiers in Oncology
  40. Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers
    Eva A. van Aalen, Simone F. A. Wouters, Dennis Verzijl, Maarten Merkx · 2022 · Analytical Chemistry
  41. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
    Samia Mourah, Baptiste Louveau, Nicolas Dumaz · 2019 · Current Opinion in Oncology
  42. Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance
    Jeļena Vasiļevska, Phil Fang Cheng, Julia Lehmann, Egle Ramelyte, Julia M. Martínez Gómez, Florentia Dimitriou, Federica Sella, Daria Ferretti, Adrián Salas-Bastos, Whitney Jordaan et al. · 2024 · Cell Reports Medicine
  43. Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial–mesenchymal transition of colon cancer cells
    Se-Hee Kim, Sangtae Choi, Won-Suk Lee · 2021 · Anti-Cancer Drugs
  44. Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets
    Nathan M. Kendsersky, Michal Odrobina, Nathaniel W. Mabe, Alvin Farrel, Liron D. Grossmann, Matthew Tsang, David Groff, Adam J. Wolpaw, Alaa Narch, Francesca Zammarchi et al. · 2025 · Neuro-Oncology
  45. The genetic and epigenetic basis of distinct melanoma types
    Junna Oba, Scott Eric Woodman · 2021 · The Journal of Dermatology
  46. Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma
    Adrian Barreno, José Luis Orgaz · 2022 · Cells
  47. Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies
    Rachel S. Goodman, Douglas Buckner Johnson · 2022 · Current Treatment Options in Oncology
  48. Pharmacokinetics and Toxicity Considerations for Antibody–drug Conjugates: An Overview
    Siddhanth Hejmady, Rajesh Pradhan, Shobha Kumari, Meghna Pandey, Sunil Kumar Dubey, Rajeev Taliyan · 2023 · Bioanalysis
  49. Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration
    Yanting Duan, Bo Hu, Chunxia Qiao, Longlong Luo, Xinying Li, Jing Wang, Hao Liu, Tingting Zhou, Beifen Shen, Ming Lv et al. · 2019 · Oncology Letters
  50. The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma
    Sebastiaan M. Schieven, Joleen J.H. Traets, Alex v. Vliet, Martijn v. Baalen, Ji‐Ying Song, Marcos Da Silva Guimaraes, Thomas Kuilman, Daniel S. Peeper · 2023 · Molecular Cancer Research
  51. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
    Ana Chocarro‐Calvo, Miguel Jociles-Ortega, José Manuel García-Martínez, Pakavarin Louphrasitthiphol, Sofia Carvalho-Marques, Yurena Vivas, Ana Ramírez-Sánchez, Jagat Singh Chauhan, Carmen Fiuza, Manuel Durán et al. · 2025 · Genes & Development
  52. Antibody-drug conjugates: an evolving approach for melanoma treatment
    Trevor S. Anderson, Amanda L. McCormick, Ninh My La-Beck, Dipongkor Saha, Devin B. Lowe · 2020 · Melanoma Research
  53. An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite
    Tim van Groningen, Camilla U. Niklasson, Alvin Chan, Nurdan Akogul, Ellen M. Westerhout, Kristoffer von Stedingk, Mohamed Hamdi, Linda J. Valentijn, Sofie Mohlin, Peter J.M. Stroeken et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Modeling stress-induced responses: plasticity in continuous state space and gradual clonal evolution
    Anuraag Bukkuri · 2024 · Theory in Biosciences
  55. Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
    Kristoffer Staal Rohrberg, Juanita Suzanne Lopez, Mohammed M. Milhem, Christian U. Blank, Irene L. M. Reijers, Fiona C. Thistlethwaite, Ruth Plummer, Sarina Anne Piha-Paul, Pasi Antero Janne, Elaine Shum et al. · 2025 · Cancer Research Communications
  56. AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
    Antonia Beitzen‐Heineke, Nikolaus Berenbrok, Jonas S. Waizenegger, Sarina Päsler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen et al. · 2021 · HemaSphere
  57. Tumor evolution-targeted nanomedicineEVT
    Lingpu Zhang, Jia‐Zhen Yang, Dongsheng Tang, Hanchen Zhang, Jianxun Ding, Haihua Xiao · 2022 · Scientia Sinica Chimica
  58. iVS analysis to evaluate the impact of scaffold diversity in the binding to cellular targets relevant in cancer
    Agostino Cilibrizzi, Giuseppe Floresta, Vincenzo Abbate, Maria Paola Giovannoni · 2018 · Journal of Enzyme Inhibition and Medicinal Chemistry
  59. Discovery and development of ADCs: obstacles and opportunities
    Hsuan‐Ping Chang, Yuen Kiu Cheung, Dhaval K. Shah · 2023 · Elsevier eBooks
  60. Insights into RAS-driven melanoma and its therapeutic implications
    Eftychia Chatziioannou, Konstantinos Lallas, Tobias W. Sinnberg, Heike Niessner, Alexander Stratigos, Lukas Flatz, Teresa Amaral · 2026 · Cancer Treatment Reviews
  61. Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations
    Ina Lami, Andrew J. Wiemer · 2024 · Drugs in R&D
  62. Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment
    Anisha Datta, Laura C. Bahlmann, Diana N. Gong, Erin N. Tevonian, James B. Lorens, Douglas A. Lauffenburger · 2025 · Frontiers in Immunology
  63. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
    Ryota Nakamura, Hiroyuki Fujii, Tadaaki Yamada, Yohei Matsui, Takeshi Yaoi, Mizuki Honda, Noriyuki Tanaka, Aya Miyagawa‐Hayashino, Akihiro Yoshimura, Kenji Morimoto et al. · 2023 · JTO Clinical and Research Reports
  64. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors
    Elena Muraro, Barbara Montico, Benedict Lum, Francesca Colizzi, Giorgio Giurato, Annamaria Salvati, Roberto Guerrieri, Aurora Rizzo, Elisa Comaro, Vincenzo Canzonieri et al. · 2024 · Frontiers in Immunology
  65. Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells
    Ting La, Lei Jin, Xiaoying Liu, Zehua Song, Margaret L. Farrelly, Yuchen Feng, Xu Guang Yan, Yuan Yuan Zhang, Rick Francis Thorne, Xu Dong Zhang et al. · 2020 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  66. An approach using Caenorhabditis elegans screening novel targets to suppress tumour cell proliferation
    Yuqin Mao, San-Feng Han, Shilong Zhang, Zheng‐Yan Zhang, Chao‐Yue Kong, Hui‐Ling Chen, Zhan‐Ming Li, Pei‐Ran Cai, Bing Han, Li‐Shun Wang · 2020 · Cell Proliferation
  67. Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles
    Larissa Anastácio da Costa Carvalho, Isabella Harumi Yonehara Noma, A. Uehara, Ádamo Davi Diógenes Siena, Luciana H. Osaki, Mateus Prates Mori, Nadja Cristhina de Souza-Pinto, Vanessa M. Freitas, Wilson A. Silva, Keiran S.M. Smalley et al. · 2024 · Antioxidants
  68. Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
    Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofía Ibáñez Molero, Beaunelle de Bruijn, Paulien Cornelissen‐Steijger, Aida Shahrabi, Martin Del Castillo Velasco‐Herrera et al. · 2021 · Clinical Cancer Research
  69. Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
    Vito W. Rebecca, Min Xiao, Andrew V. Kossenkov, Tetiana Godok, Gregory Schuyler Brown, Dylan F. Fingerman, Gretchen Marie Alicea, Meihan Wei, Hongkai Ji, Jeremy Bravo et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  70. Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy
    Gunsagar Singh Gulati, Toni K. Choueiri, Matthew L. Freedman, Sylvan C. Baca · 2026 · Journal of Clinical Oncology
  71. The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance
    Stephen M. Ostrowski, David E. Fisher · 2021 · Journal of Investigative Dermatology
  72. Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells
    Xuejun Gao, Dandan Xue, Jingjing Cheng, Xin Zhang, Xia Cai · 2022 · Journal of Oncology
  73. A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma
    Jing Huang, Hongqi Huo, Rong Lu · 2022 · Frontiers in Genetics
  74. Research progress of antibody–drug conjugates in gynecologic cancer
    Dongdong Xu, Zhe‐Sheng Chen, Xuanwei Peng, Zhongqiu Lin, Huaiwu Lu · 2024 · Holistic Integrative Oncology
  75. High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody–drug conjugate targeting Trop-2 is a promising therapeutic approach
    Xiaoying Qian, Chuanhong Luo, Fang Chen, Yongbin Wu, Weiwei Hong, Biao Yu, Guizhen Qin, Yan Yin, Xinyuan Yao, Xin Ye et al. · 2025 · Journal of Translational Medicine
  76. Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells
    Signe Caksa, Timothy J. Purwin, Dan A. Erkes, Kristen M. DeRosa, Erica L. Kitterman, Samantha M. Barnada, Casey D. Stefanski, Haley P. Wilson, Glenn L. Mersky, McKenna Q. Glasheen et al. · 2025 · Cancer Research
  77. The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer—From Pathophysiology to Therapeutic Impact
    Oliver Daniel Schreiner, Thomas Gabriel Schreiner, Lucian Miron, Romeo Cristian Ciobanu · 2025 · Medicina
  78. The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer
    Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa · 2023 · Future Oncology
  79. Membrane protein regulators of melanoma pulmonary colonization identified using a CRISPRa screen and spontaneous metastasis assay in mice
    Louise van der Weyden, Victoria Offord, Gemma Turner, Agnes Swiatkowska, Anneliese O. Speak, David J. Adams · 2021 · G3 Genes Genomes Genetics
  80. The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma
    Mai Bdarny, Manu Prasad, Noa Balaban, Ben‐Zion Joshua, Anat Bahat Dinur, Reidar A. Grenman, Limor Cohen, Moshe Elkabets · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  81. Phenotype-specific melanoma uptake of fatty acid from human adipocytes activates AXL and CAV1-dependent β-catenin nuclear accumulation
    Ana Chocarro‐Calvo, Miguel Jociles-Ortega, José Manuel García-Martínez, Pakavarin Louphrasitthiphol, Yurena Vivas, Ana Ramírez-Sánchez, Jagat Singh Chauhan, Carmen Fiuza, Manuel Durán, Custodia García‐Jiménez et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Multistage Biobarrier-Adaptive Peptide Radiosensitizer with Low-Dose X-ray Augments Glioblastoma Radiotherapy via Destabilizing Lysosomal Homeostasis
    Xueyin Hu, Wei Cheng, Jun Che, Yuanfang Chen, Yue Shang, Cong Gao, Changfen Bi, Saijun Fan, Shuqin Li, Luntao Liu · 2025 · ACS Nano
  83. RTK AXL and its Isoforms: Regulation and Implications in Cancer
    Ilona Malikova, Aizhan Syzdykova, Nazia Islam, Marina Kriajevskaia, Eugene M. Tulchinsky · 2026 · Current Medicinal Chemistry
  84. Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates
    Zhuoliang Hu, Yuheng Liao, Mengxian Niu, Zhanghong Kong, Hugo E J Vankelecom, Jianjun Cheng, Michela Deleidi, Chenzhong Li, Zhengjin Jiang, Sumin Bian et al. · 2026 · Acta Pharmaceutica Sinica B
  85. Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms
    Anna Meiliana, Andi Wijaya · 2023 · The Indonesian Biomedical Journal
  86. Cancer research driven by cutting-edge multi-disciplinary technologies
    Qunyan Lyu, Yukuan Feng, Rong Shi, Jing Wu, Weidong Han · 2020 · Chinese Science Bulletin (Chinese Version)
  87. Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
    Tara L. Peters, Nan Chen, Logan C. Tyler, Anh Tuan Le, Anastasios Dimou, Robert Charles Doebele · 2023 · Thoracic Cancer
  88. Gain-of-function CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and therapy-resistance
    Arthur Gautron, Laura Bachelot, Anaïs M. Quéméner, Sébastien Corre, Marc Aubry, Florian Rambow, Anaïs Paris, Nina Tardif, Héloïse M. Leclair, Cédric Coulouarn et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  89. Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
    D. Castelletti, J. Hinrichs, G. Malojčić, Fei Ji, Aurore Desplat, B. Reimer, Christelle Henry, Kathryn A. Porter, Fanny Mermet-Meillon, Markus Wartmann et al. · 2025 · Nature Communications
  90. Antibody–Drug Conjugates: The Past, Present and Future
    Gail D. Lewis Phillips · 2025 · Annual Review of Cancer Biology
  91. Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance
    Zuming Yang, Shuaishuai Cao, Jiaen Zhang, Xiaohua Nie, Zhimin Wang, Shaojun Yang, Jingshu Wang, Xin Sun, Xueli Kuang, Huiming Huang et al. · 2026 · Signal Transduction and Targeted Therapy
  92. Nonepithelial cancer dissemination: specificities and challenges
    Serena Diazzi, Julien Ablain · 2023 · Trends in cancer
  93. Drug sales confirm clinical advantage of multi‐target inhibition of drug escapes by anticancer kinase inhibitors
    Shangying Chen, Sheng Yong Yang, Zhe Chen, Ying Ching Tan, Yu Yang Jiang, Yu Chen · 2018 · Drug Development Research
  94. TAM family proteins and therapy resistance
    Nellie K. McDaniel, Samantha R. Fischbach, Olivia J. Ondracek, Noah B. Welke, Mari Iida, Deric L. Wheeler · 2020 · Elsevier eBooks
  95. Targeted Therapies for BRAF-Mutant Metastatic Melanoma
    Douglas Buckner Johnson, Reinhard Dummer, Keith T. Flaherty, Keiran S.M. Smalley · 2018 · Springer eBooks
  96. Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching
    Margaux Sala, Nathalie Allain, Arnaud Jabouille, Elodie Henriet, Aya Abou Hammoud, Arnaud Uguen, Sylvaine Di-Tommaso, Cyril Dhourte, Anne‐Aurélie Raymond, Jean‐William Dupuy et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  97. Targeted Therapies for BRAF-Mutant Metastatic Melanoma
    Douglas Buckner Johnson, Reinhard Dummer, Keith T. Flaherty, Keiran S.M. Smalley · 2020 · Springer eBooks
  98. The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance
    Maria Lie Lotsberg, Kjersti T. Davidsen, Stacey D’mello Peters, Gry Sandvik Haaland, Austin J. Rayford, James B. Lorens, Agnete S. T. Engelsen · 2022 · Springer eBooks
  99. Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma
    Daniel S. Peeper, Sebastiaan M. Schieven, Joleen J.H. Traets, Alex v. Vliet, Martijn v. Baalen, Ji‐Ying Song, Thomas Kuilman · 2022 · Research Square
  100. Data from Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
    Ellen M. Westerhout, Mohamed Hamdi, Peter J.M. Stroeken, Natalia E. Nowakowska, Arjan Lakeman, Jennemiek van Arkel, Nancy E. Hasselt, Boris Bleijlevens, Nurdan Akogul, Franciska Haneveld et al. · 2023